Contact
Please use this form to send email to PR contact of this press release:
MSI Methylation Sciences Inc. (MSI) Announces Results From the Horizon Phase 2 Trial for its Novel Treatment, MSI-195, for Major Depressive Disorder (MDD)
TO: